MindWalk Holdings Corp. (NASDAQ:HYFT) Receives $5.00 Consensus Target Price from Brokerages

Shares of MindWalk Holdings Corp. (NASDAQ:HYFT) have received a consensus recommendation of “Hold” from the five analysts that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $5.00.

Several research firms have recently commented on HYFT. Weiss Ratings restated a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. Wall Street Zen upgraded shares of MindWalk from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Zacks Research lowered shares of MindWalk from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 28th. Finally, HC Wainwright reissued a “buy” rating on shares of MindWalk in a research note on Monday, July 20th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in MindWalk stock. GSA Capital Partners LLP purchased a new position in MindWalk Holdings Corp. (NASDAQ:HYFT) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 34,525 shares of the company’s stock, valued at approximately $55,000. GSA Capital Partners LLP owned approximately 0.07% of MindWalk at the end of the most recent quarter. 6.70% of the stock is currently owned by institutional investors and hedge funds.

MindWalk Stock Performance

Shares of MindWalk stock opened at $1.16 on Friday. The firm has a market cap of $53.95 million, a P/E ratio of -4.44 and a beta of 0.82. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.26. MindWalk has a 12 month low of $0.99 and a 12 month high of $2.99. The stock’s fifty day moving average price is $1.37 and its 200-day moving average price is $1.36.

MindWalk (NASDAQ:HYFT) last released its quarterly earnings data on Monday, September 14th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). MindWalk had a negative return on equity of 115.41% and a negative net margin of 105.11%.The business had revenue of $2.73 million during the quarter. On average, equities research analysts expect that MindWalk will post -0.21 earnings per share for the current fiscal year.

Key MindWalk News

Here are the key news stories impacting MindWalk this week:

• Positive Sentiment: Fiscal Q1 2027 revenue increased 21.3% year over year to approximately $3.8 million, while gross profit rose 47.1% to $2.2 million. Gross margin expanded to 58.6% from 48.3%, suggesting improving economics as the company shifts toward higher-margin, recurring platform revenue. MindWalk Reports 21% Revenue Growth
• Positive Sentiment: MindWalk commercially launched ReefIQ, its data platform, potentially supporting a transition toward recurring, platform-based revenue and expanding its Bio-Native AI business. MindWalk Revenue and ReefIQ Launch
• Positive Sentiment: The company secured a binding commitment for up to $30 million through a senior unsecured revolving credit facility. The 7% fixed-rate facility has no warrants, equity-conversion features, or financial maintenance covenants, allowing MindWalk to fund biologics programs, commercial expansion, and working capital without immediate shareholder dilution. MindWalk $30 Million Credit Facility
• Neutral Sentiment: Management’s Q1 earnings call focused on ReefIQ’s commercial launch, the company’s platform strategy, and funding for expansion. The transcripts provide additional context but do not change the headline financial results. MindWalk Q1 2027 Earnings Call Transcript
• Negative Sentiment: MindWalk reported a fiscal Q1 loss of $0.09 per share, worse than the $0.05 consensus loss and the $0.07 loss recorded a year earlier. Continued losses, negative margins, and reliance on future growth remain significant risks. MindWalk Reports Q1 Loss
• Negative Sentiment: Although the credit facility avoids dilution, any drawn funds will accrue interest at 7%, increasing financing costs for a company that remains unprofitable.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.